Activated Recombinant Factor VII (rFVIIa) in Bleeding Management after Therapy with llb/llla-Inhibitor Tirofiban

• References

• 1 Task Force Members. Bertrand ME, Simoons ML, Fox KAA. et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Eur Heart J 2000; 21: 1406-32.
• 2 PRISM-PLUS Study Investigators: Inhibition of the Platelet Glycoprotein Ilb/IIIa Receptor with Tirifiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. N Engl J Med. 1998; 338: 1488-97.
• 3 Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 629: 35.
• 4 Poon M-C. d’Oiron R and the International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrynolysis 2000; 11 (Suppl. 01) S55-S68.
• 5 Lusher J, Ingerslev J, Roberts Ft, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrynolysis 1998; 09 (Suppl. 01) 119-28.
• 6 Poon M-C, Demers C, Jobin F, Wu JWY. Recombinant Factor VIIa is effective for Bleeding and Surgery in Patients with Glanzmann Thrombasthenia. Blood 1999; 94: 3951-3.